MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,773.95
+0.66%
NASDAQ 100
$31,076.44
+0.87%
DOW JONES
$51,268.00
+0.18%
NASDAQ Composite
$27,477.31
+1.05%
RUSSELL 2000
$2,833.80
+0.66%
CBOE VIX
$15.52
+1.37%
Sector Heatmap
Technology+0.56%
Financials+0.73%
Healthcare+0.72%
Consumer Cycl+0.35%
Consumer Staples+0.63%
Energy+0.99%
Industrials+0.09%
Materials+1.31%
Real Estate-0.34%
Utilities+0.35%
Comm Services+1.17%
INMB — INmune Bio Inc. Common stock
NasdaqINmune Bio Inc. Common stock
$1.94
+0.01(+0.52%)
- O
- 1.90
- H
- 1.97
- L
- 1.88
- V
- 266.74K
⏱️ End-of-day dataAs of Oct 5, 2026
Chart
About INMB
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SectorNot available
IPO DateFeb 4, 2019
Employees21
Stock ExchangeNasdaq
Ticker SymbolINMB
Websitehttps://www.inmunebio.com
Key Financial Statistics
| Market Cap | $53.56M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $1.09 - $2.60 |
| 52-Week Avg Volume | 484.4K |
| VWAP | $1.93 |
| Transactions | 1,613 |
| Total Recorded Bars | 1,928 days |